Chronic Venous Insufficiency Pipeline 2025: MOA And ROA Insights, Clinical Trials Status, And Key Companies Involved By Delveinsight Endovenous Valve System, Innovein Valve Treatment, Biovena

(MENAFN- GetNews)

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Venous Insufficiency pipeline constitutes key companies continuously working towards developing Chronic Venous Insufficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Chronic Venous Insufficiency Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Venous Insufficiency Market.

The Chronic Venous Insufficiency Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Venous Insufficiency Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Venous Insufficiency treatment therapies with a considerable amount of success over the years.

• Chronic Venous Insufficiency companies working in the treatment market are Verigraft AB, TR Therapeutics, Alfasigma, and others, are developing therapies for the Chronic Venous Insufficiency treatment

• Emerging Chronic Venous Insufficiency therapies in the different phases of clinical trials are- P-TEV, TR 987, Sulodexide, and others are expected to have a significant impact on the Chronic Venous Insufficiency market in the coming years.

• In July 2025, TR Therapeutics shared findings from a Phase 3 randomized, double-blind, parallel-group study assessing the efficacy, tolerability, and safety of TR987® 0.1% Gel compared to the standard of care for treating leg ulcers caused by chronic venous insufficiency.

• In October 2024, InterVene, Inc., a clinical-stage medical device company specializing in interventional therapies for chronic venous insufficiency (CVI), announced the successful closure of its $13 million Series A funding round. The round was co-led by new investor Treo Ventures and returning investor RiverVest Venture Partners®. Additionally, Brad Vale, founding general partner at Treo Ventures, joined InterVene's Board of Directors as part of the investment.

• In April 2024, EnVVeno Medical unveiled encouraging top-line effectiveness findings from its SAVVE clinical investigation of the VenoValve, revealing that 94% of participants utilizing the valve exhibited clinical enhancement. The VenoValve, a pioneering surgical substitute venous valve, is under development to address deep venous chronic venous insufficiency (CVI). Engineered as a novel one-way valve, it aims to facilitate blood propulsion up the leg, aiding its return to the heart and lungs.

Chronic Venous Insufficiency Overview

Chronic Venous Insufficiency is a condition characterized by poor blood flow in the veins, usually in the legs. It occurs when the valves in the veins that help blood flow back to the heart become damaged or weakened, leading to a buildup of blood in the veins and increased pressure in the lower limbs.

Get a Free Sample PDF Report to know more about Chronic Venous Insufficiency Pipeline Therapeutic Assessment-

Emerging Chronic Venous Insufficiency Drugs Under Different Phases of Clinical Development Include:

• P-TEV: Verigraft AB

• TR 987: TR Therapeutics

• Sulodexide: Alfasigma

Chronic Venous Insufficiency Pipeline Therapeutics Assessment

• Chronic Venous Insufficiency Assessment by Product Type

• Chronic Venous Insufficiency By Stage and Product Type

• Chronic Venous Insufficiency Assessment by Route of Administration

• Chronic Venous Insufficiency By Stage and Route of Administration

• Chronic Venous Insufficiency Assessment by Molecule Type

• Chronic Venous Insufficiency by Stage and Molecule Type

DelveInsight's Chronic Venous Insufficiency Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Venous Insufficiency product details are provided in the report. Download the Chronic Venous Insufficiency pipeline report to learn more about the emerging Chronic Venous Insufficiency therapies

Some of the key companies in the Chronic Venous Insufficiency Therapeutics Market include:

Key companies developing therapies for Chronic Venous Insufficiency are - EVVS: EndoVenous Valve System, InnoVein Valve Treatment, BioVena, VenoValve, and others.

Chronic Venous Insufficiency Pipeline Analysis:

The Chronic Venous Insufficiency pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Venous Insufficiency with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Venous Insufficiency Treatment.

• Chronic Venous Insufficiency key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Venous Insufficiency Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Venous Insufficiency market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Venous Insufficiency drugs and therapies

Chronic Venous Insufficiency Pipeline Market Drivers

• Improving Healthcare Infrastructure, increase in the awareness related to the treatment of the disease are some of the important factors that are fueling the Chronic Venous Insufficiency Market.

Chronic Venous Insufficiency Pipeline Market Barriers

• However, limited number of drugs in the pipeline, under diagnosis of the disease and other factors are creating obstacles in the Chronic Venous Insufficiency Market growth.

Scope of Chronic Venous Insufficiency Pipeline Drug Insight

• Coverage: Global

• Key Chronic Venous Insufficiency Companies: Verigraft AB, TR Therapeutics, Alfasigma, and others

• Key Chronic Venous Insufficiency Therapies: P-TEV, TR 987, Sulodexide, and others

• Chronic Venous Insufficiency Therapeutic Assessment: Chronic Venous Insufficiency current marketed and Chronic Venous Insufficiency emerging therapies

• Chronic Venous Insufficiency Market Dynamics: Chronic Venous Insufficiency market drivers and Chronic Venous Insufficiency market barriers

Request for Sample PDF Report for Chronic Venous Insufficiency Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Venous Insufficiency Report Introduction

2. Chronic Venous Insufficiency Executive Summary

3. Chronic Venous Insufficiency Overview

4. Chronic Venous Insufficiency- Analytical Perspective In-depth Commercial Assessment

5. Chronic Venous Insufficiency Pipeline Therapeutics

6. Chronic Venous Insufficiency Late Stage Products (Phase II/III)

7. Chronic Venous Insufficiency Mid Stage Products (Phase II)

8. Chronic Venous Insufficiency Early Stage Products (Phase I)

9. Chronic Venous Insufficiency Preclinical Stage Products

10. Chronic Venous Insufficiency Therapeutics Assessment

11. Chronic Venous Insufficiency Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Venous Insufficiency Key Companies

14. Chronic Venous Insufficiency Key Products

15. Chronic Venous Insufficiency Unmet Needs

16 . Chronic Venous Insufficiency Market Drivers and Barriers

17. Chronic Venous Insufficiency Future Perspectives and Conclusion

18. Chronic Venous Insufficiency Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

MENAFN01082025003238003268ID1109873079